Background: This study aims to determine the effects of artesunate on proliferation, apoptosis and β-catenin expression in the human osteosarcoma cell line MG-63. Methods: MG-63 cells in the logarithmic growth phase were collected and cultured with different concentrations of artesunate (12.5 µg/mL, 25 µg/mL and 50 µg/mL) for 24 h, 48 h and 72 h. The total number of MG-63 cells and the morphological changes were observed under an inverted microscope. The MTT assay was adopted to test the inhibition rate (IR) of cell growth. The apoptosis rate was detected using annexin V/propidium iodide (PI) staining. Cell cycle distribution was identified by flow cytometry (FCM), and the expression levels of β-catenin, cyclins and cyclin dependent kinases (CDKs) were measured using Western blotting. Results: The results of the MTT assay indicated that artesunate could remarkably inhibit MG-63 cell proliferation compared with the rates in the untreated control group (0 µg/mL artesunate), and the inhibitory effect was dose-dependent. The apoptosis rate of MG-63 cells was elevated as the concentration of artesunate increased, and all the rates were significantly higher than that in the control group. Additionally, as the artesunate concentration increased, the proportion of MG-63 cells in G0/G1 phase gradually declined whereas that of cells in the G2/M and S phases increased. Western blotting confirmed that a higher concentration of artesunate reduced the expression levels of β-catenin, cyclin A, cyclin D1 and CDK1 and increased the expression levels of cyclin B1; however, artesunate had no impact on CDK2 expression in MG-63 cells. Conclusion: These results demonstrated that artesunate can inhibit β-catenin expression and cell proliferation as well as promote cell apoptosis in MG-63 cells, which indicates that artesunate may serve as a promising drug in the clinical treatment of osteosarcoma.
Introduction
As one of the most common primary malignant bone tumors in the world, osteosarcoma is a highly malignant mesenchymal-based tumor that mainly presents in children and teenagers [1, 2] . The annual morbidity of osteosarcoma is approximately 5 million cases worldwide [3] with prevalence towards males at a ratio of 1.5 : 1. The knee joint periphery is a common pathogenic site [4] , and the main clinical symptoms include pain, swelling, dysfunction, weight loss and anemia [5] . To date, the pathogenesis of osteosarcoma remains unclear, but Ottaviani et al. reported that this disease was related to both environmental and genetic factors [6] . The combined use of neoadjuvant chemotherapy (NACT) and surgical resection is the current first-line treatment strategy for osteosarcoma, which has greatly improved the 5-year survival rate of osteosarcoma patients to about 80% [7, 8] . However, the effectiveness of this therapy has achieved little improvement in the past 20 years. Recent evidence has shown that pulmonary metastasis is the leading cause of death among osteosarcoma patients, and toxic side effects as well as multidrug resistance to traditional agents were too pronounced to provide any benefit to some patients [9] . Therefore, it is extremely urgent to develop new anti-osteosarcoma drugs.
Natural agents, in combination with conventional treatments, are proved to be novel options for the treatment of cancers and some of natural agents such as allicin, curcumin and formononetin play a crucial role in anticancer activities [10] . Artesunate is a major artemisinin derivative extracted from Artemisia apiacea and is often used to treat malaria [11] . A previous report indicated that artesunate could inhibit the growth of various tumors and induce cell apoptosis [12] . Moreover, it was reported that concomitant administration of conventional chemotherapeutic agents and artesunate could significantly extend the lifespan of patients with metastatic uveal melanoma [13] . Another study also showed that the Wnt/β-catenin signaling pathway was closely related to the formation, translocation and apoptosis of osteosarcoma [14] . β-catenin, a central molecule in the Wnt/β-catenin pathway, exhibited an abnormal expression pattern in osteosarcoma and was associated with osteosarcoma translocation [15] . Hence, reducing β-catenin expression and inhibiting the Wnt/β-catenin pathway could be targets for osteosarcoma treatment. Nevertheless, since many previous studies have specifically focused on the role of dihydroartemisinin in osteosarcoma, and studies regarding artesunate and β-catenin in osteosarcoma are rare, this study aims to investigate the impact of artesunate on the proliferation and apoptosis of MG-63 cells as well as on β-catenin protein expression in osteosarcoma in a systematic and complete manner with the goal of providing basic in vitro data for the clinical treatment of tumors using artemisinin-based drugs.
Materials and Methods

Cell culture and grouping
The human osteosarcoma cell line MG-63 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), and then diluted (1 : 10) with Roswell Park Memorial Institute (RPMI) 1640 culture medium (Beijing Thermo Fisher Scientific Company, Beijing, China). These cells were suspended and then centrifuged at a low speed (1000 rpm/ min) for 8 min (Heraeus Company, Germany). After repeating the above steps 3 times, the cell pellet was re-suspended and added into a culture flask (Beijing Thermo Fisher Scientific Company, Beijing, China) for adherent growth in Dulbecco's Modified Eagle's Medium (DMEM) sugar nutrient solution (HyClone Company, Logan, UT, USA; item No. 31600-034) containing 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin; these cells were cultured at 37℃ in an incubator with saturated humidity and 5% CO 2 (SHEL LAB Company, USA). These cells were passaged every 2 to 3 days with cells in the logarithmic growth phase collected for experiments. Artesunate (60 mg/strip; Shanghai Fosun Pharmaceutical Limited Company, Shanghai, China; No: H10930195) was obtained. A total of 100 µg of artesunate was collected and dissolved in 1 mL of dimethyl sulfoxide (DMSO) (Sigma-Aldrich Company, USA) to prepare 100 µg/mL stock solution that was then diluted using RPMI1640 Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry into different concentrations of working solutions (12.5 µg/mL, 25 µg/mL and 50 µg/mL), which were defined as the A1 group, A2 group and A3 group respectively. The cells were cultivated for 24 h, 48 h and 72 h as appropriate, sterilized using ultrafiltration and preserved at -20℃. In addition, a group cultured without RPMI 1640 medium was used as the control group.
Observation of the number and morphological changes of MG-63 cells
MG-63 cells in the logarithmic growth phase were collected and seeded into a 24-well plate for culturing. After the cells attached, different concentrations of artesunate were added to the plate, and the cells were cultured for 48 h, after which the morphology of cells treated with different concentrations of artesunate was observed under an inverted microscope (Olympus Co., Ltd, China).
MTT assay MG-63 cells in the logarithmic growth phase were collected, digested using 0.25% pancreatic enzymes, and then diluted into single-cell suspensions using phosphate-buffered solution (PBS). These cells were seeded into 96-well plates at 2 × 10 4 cells per well (100 µL per well) and then cultured at 37°C in an incubator containing 5% CO 2 . After complete cell attachment, 100 µL of different concentrations of artesunate (12.5 µg/mL, 25 µg/mL and 50 µg/mL) was added to the cells as appropriate, while no artesunate was added to cells in the control group. A total of 100 µL of RPMI 1640 nutrient solution was then added into wells, with each condition performed in duplicate. In addition, 2 wells in each 96-well plate only received 200 µL of nutrient solution as a blank control. The plates were taken out after the cells were incubated with artesunate for 24 h, 48 h and 72 h, and 20 µL of MTT solution (5 mg/mL) (Wuhan Boster Biotechnology Limited Company, Wuhan, China; item No. AR1156) was added into all the wells. After another time of incubation for 4 h at 37°C, the nutrient solution in each well was discarded, and 150 µL of DMSO was added to each well. The plates were shaken on a shaking table for 8 min. When the crystals were fully dissolved, the blank wells were used to zero the plate reader. The optical density (OD) of each well was detected at 490 nm using an enzyme-linked immunosorbent assay (ELISA) to analyze the inhibition and survival rates of the cells. The formulas for these rates are as follows: inhibition rate (IR) = (OD value in the control group -OD value in the treated group) / OD value in the control group × 100%; survival rate (SR) = OD value in the treated group / OD value in the control group × 100%.
Annexin V/propidium iodide (PI) staining
The density of the osteosarcoma cells in the logarithmic growth phase was adjusted to 1 × 10 6 cells/ mL, after which the cell suspension was seeded into a 12-well plate (Becton Dickinson Company, USA). A total of 2 mL of cell suspension and 2 mL of artesunate at different concentrations were added into each well with the final artesunate concentration in each group as 0 µg/mL, 12.5 µg/mL, 25 µg/mL and 50 µg/mL. After cells were incubated for 48 h at 37°C, 1 mL of cell suspension per well was collected and centrifuged at 1000 r/min for 10 min at 4℃, after which the supernatant was removed. Then, 1 mL of cold PBS was added to the cell pellet, which was shaken lightly to resuspend the cells. The cells were centrifuged at 1000 r/min at 4℃ for 10 min, and the supernatant was removed. These wash steps were repeated twice. The cells were then resuspended in 200 µL of PBS, to which 10 µL of fluorescein isothiocyanate (FITC)-labeled annexin V (Annexin V-FITC) (Beijing Biosea Biotechnology Co., LTD) was added. The mixture was gently mixed and incubated in the dark at room temperature for 15 min. A total of 300 µL of PBS and 5 µL of PI were then added (Promega Corporation, USA), and flow cytometry (FCM) was conducted to test the levels of apoptotic cells (FACS Calibur Company, USA).
FCM detection
Osteosarcoma cells (1 × 10 5 cells/mL) in the logarithmic growth phase were seeded in 24-well plates (Becton Dickinson Company, USA) at a volume of 1 mL per well. A total of 3 groups were established with each condition performed in triplicate. In addition, 1 mL of artesunate solution was added to each group to final concentrations of 0 µg/mL, 12.5 µg/mL, 25 µg/mL and 50 µg/mL. Cells were cultured for 48 h at 37°C under saturated humidity with 5% CO 2 . After that, the cells were harvested, washed once with PBS, and centrifuged to remove residual PBS. The cells were then fixed with 70% ethanol at 4°C for 1 h, centrifuged and washed by PBS another 3 times, after which the PBS was removed via centrifugation. The plates were added to a 37°C water bath for 30 min after adding RNA enzyme. Subsequently, 800 µL of PI was added, mixed with cell solution and reacted with cells at 4°C in the dark for 30 min. The distribution of cells throughout the cell cycle was detected using FCM.
Western blotting MG-63 cells treated with different concentrations of artesunate for 48 h were collected and established as their respective treatment groups. The cell density was 1 × 10 7 cells per flask (Becton Dickinson Company, USA), and the group without artesunate was used as the control group. A protein extraction reagent (Wuhan Boster Biotechnology Limited Company, Wuhan, China) was used to extract the proteins, and a BCA kit (Wuhan Boster Biotechnology Limited Company, Wuhan, China) was applied to measure the protein levels. Extracted proteins were separated using polyacrylamide electrophoresis on a 10% gel (Wuhan Boster Biotechnology Limited Company, Wuhan, China) and transferred to a polyvinylidene fluoride (PVDF) membrane. When the membrane transfer finished, the membranes were placed on a horizontal shaking table and blocked for 1 h with PBS containing either 5% bovine serum albumin (BSA) or dissolved skim milk powder. The sealed PVDF membrane was removed and incubated at 4°C overnight with the following primary antibodies (100 μL/cm Company, USA). The secondary antibody was diluted in 5% BSA (Beyotime Biotechnology Co., Shanghai, China; item No: A7007) at a density of 100 μl/cm 2 and was added to the membranes, which were then sealed and incubated on a shaking table at room temperature for 1 h. Equal volumes of detection reagents A and B were mixed in a petri dish with no strong light throughout the procedure. The PVDF membrane (Bio-Rad Company, USA) immersed in PBS was placed in ECL working solution for color development, and was scanned using the Bio-Rad GelDoc 2000 gel imaging system. Image analysis and processing were conducted by Image Lab. Gray values of protein bands were quantitatively analyzed, with the gray value of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band as the reference.
Statistical analysis
Data were analyzed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Measurement data are presented as the mean ± standard deviation (SD). Comparisons of normally distributed measurement data between two groups were conducted using the t-test, and comparisons among multiple groups were determined using one-way analysis of variance (ANOVA). Numeric data are presented as either ratios or percentages, and the chi-square test was applied to compare between two groups. P < 0.05 was considered statistically significant.
Results
Artesunate-induced damage of the morphology of MG-63 cells
Forty-eight hours after MG-63 cells were treated with artesunate at final concentrations of 0 µg/mL, 12.5 µg/mL, 25 µg/mL and 50 µg/mL, visualization under a normal inverted microscope showed that in the treated groups with an increasing artesunate concentration, the cells exhibited a worse growth status, the number of cells gradually decreased, the cell size was smaller and the number of floating dead cells was increased. However, in the control group, there were many cells, the cell nuclei were relatively larger, the cytosol area was plentiful, and cells were healthy (Fig. 1) . 
Artesunate inhibits the proliferation of MG-63 cells
The MTT method was adopted to detect the role of artesunate in the proliferation of MG-63 cells in vitro, and the results shown in Fig. 2 indicate that artesunate could significantly inhibit the growth of MG-63 cells. As the concentration of artesunate increased, its inhibitory effect on cell proliferation was enhanced, which indicates dose-dependent inhibition within a certain period. Compared with the control group (0 µg/mL artesunate), MG-63 cells treated with 12.5 µg/mL, 25 µg/mL or 50 µg/mL artesunate showed a significantly reduced IR at 24 h, 48 h and 72 h (all P < 0.01) ( Table  1) . Using the Logit method, the half maximal inhibitory concentration (IC 50 ) of artesunate at 24 h, 48 h and 72 h was 39.19 µg/mL, 27.51 µg/mL and 22.91 µg/mL, respectively. Thus, these data suggest that artesunate could inhibit the growth of MG-63 cells.
Artesunate promotes the apoptosis of MG-63 cells
The results of annexin V/PI double staining show that the natural apoptosis rate of MG-63 cells in the control group was relatively low. After MG-63 cells were treated with 12.5 µg/ mL, 25 µg/mL or 50 µg/mL artesunate for 48 h, their apoptosis rates were 23.91%, 33.75% and 52.97%, respectively, which indicates that with increasing artesunate concentrations, the cell apoptosis rate gradually increased (all P < 0.05). The apoptosis rate of MG-63 cells in the three groups treated with artesunate was significantly higher than that in the control group (all P < 0.05) (Fig. 3, Table 2 ).
Effect of artesunate on the cell cycle distribution of MG-63 cells
FCM detection of the cell cycle distribution of MG-63 cells treated with 0 µg/mL, 12.5 µg/mL, 25 µg/mL or 50 µg/mL artesunate for 48 h is shown in Fig. 4 . The results indicate that as the artesunate concentration increased, the number of cells in G0/G1 phase gradually decreased, whereas that of cells in the G2/M and S phases gradually increased. In addition, the differences between the control group and the treatment groups were all statistically significant (all P < 0.05) ( Table 3) . 
Expression of β-catenin and cell cycle-related proteins in MG-63 cells after treatment with artesunate
Western blotting analysis indicated that at 48 h after treatment with different concentrations of artesunate, all the treatment groups showed decreased protein expression of β-catenin, and the β-catenin protein expression gradually fell as the artesunate concentration increased (Fig. 5) . In addition, concomitant with increases of the artesunate concentration, the protein expression levels of cyclin A, cyclin D1 and CDK1 gradually decreased, whereas those of cyclin B1 gradually increased. Differences between the control Table 2 . Apoptosis rate of the MG-63 cells treated with artesunate with different concentrations for 48 h, A1, the group treated with 12.5 μg/ml artesunate; A2, the group treated with 25 μg/ml artesunate; A3, the group treated with 50 μg/ ml artesunate; *, P < 0.05 when in comparison with the control group Table 2 . Apoptosis rate of the MG-63 cells treated with artesunate with different concentrations for 48 h, A1, the grou with 12.5 μg/ml artesunate; A2, the group treated with 25 μg/ml artesunate; A3, the group treated with 50 μg/ml art *, P < 0.05 when in comparison with the control group.
Groups
Concentrations (µg/ml) Apoptosis ratio (%) Control group 0 6.10 ± 0.25 A1 group 12.5 23.91 ± 2.61* A2 group 25 33.75 ± 1.85* A3 group 50 52.97 ± 6.32* Table 3 . Cell cycle distribution changes of the MG-63 cells treated with artesunate with different concentrations for 48 h. Notes: A1, the group treated with 12.5 μg/ml artesunate; A2, the group treated with 25 μg/ml artesunate; A3, the group treated with 50 μg/ml artesunate; *, P < 0.05 when in comparison with the control group; #, P < 0.05 when in comparison with the A3 group ble 3. Cell cycle distribution changes of the MG-63 cells treated with artesunate with different concentrations for 48 h otes: A1, the group treated with 12.5 μg/ml artesunate; A2, the group treated with 25 μg/ml artesunate; A3, the grou eated with 50 μg/ml artesunate; *, P < 0.05 when in comparison with the control group; #, P < 0.05 when in compariso ith the A3 group GAPDH, glyceraldehyde-3-phosphate dehydrogenase; *, P < 0.05 compared with the blank control group.
group and the treatment groups were all statistically significant (all P < 0.05). However, the protein expression of CDK2 showed no significant differences among all the groups (P > 0.05) (Fig. 6 ).
Discussion
Artemisinin, a widely used medical herb derived from the sweet woodworm Artemisia annua to treat fever, has long been proven to be of great therapeutic value in the treatment of diabetes, malaria, ferroptosis, atherosclerosis and other diseases [16] [17] [18] [19] . Recent studies indicated that artesunate can induce high anti-tumor activity in vitro and in vivo as evidenced by its inhibitory effects on breast carcinoma [20] , lung cancer [21] , pancreatic carcinoma [22] , prostatic cancer [23] and skin cancer [24] . Therefore, this study aims to determine the impact of artesunate on the proliferation and apoptosis of MG-63 cells as well as on β-catenin expression thus further expanding China's research on artemisinin-based therapies in the field of pharmacology. In addition, the results in this study showed that artesunate could reduce β-catenin expression, inhibit the proliferation and promote apoptosis of human osteosarcoma cells, which lends artesunate as a new and promising drug in the clinical treatment of osteosarcoma.
An in vitro experiment showed that artesunate could remarkably inhibit the proliferation of MG-63 cells in a dose-dependent manner [25] . Recently, Xu et al. demonstrated that the antitumor mechanism of artesunate was achieved by inhibiting cell cycle progression and inducing apoptosis in human osteosarcoma cells in vitro and in vivo [26] . In this study, FCM was used to detect changes in cell cycle progression, and it was found that as the artesunate concentration increased, the proportion of MG-63 cells in the G2/M and S phases gradually increased while the proportion of cells at G0/G1 phase gradually decreased, which indicated that artesunate inhibited the progression of cell cycle thereby restraining cell proliferation. Dong et al. also observed similar findings in a study regarding the in vitro inhibition of artemisinin and artesunate on the human breast carcinoma cell line Michigan cancer foundation-7 (MCF-7), which supports the notion that artesunate exerted stronger inhibitory effect on MCF-7 cells than artemisinin [20] . Additionally, artesunate could induce DNA double-bond breakage in tumor cells and down-regulate the expression of homologous recombinant protein [27] . Homologous recombinant protein is a key factor in the repair of homologous recombination, and down-regulated expression of this protein could decrease the repair capacity of tumor cells. Therefore, artesunate was likely to block cell cycle progression by enhancing the level of DNA damage and thereby achieving the inhibitory effect on tumor cell proliferation.
Cell apoptosis is also known as programmed cell death, and its occurrence is accompanied by complex signal transduction pathways and control mechanisms [28] . To date, it has been acknowledged that cell apoptosis occurs via regulation of mitochondria, death receptors and endoplasmic reticulum signals. A previous study have verified that formononetin, an important natural anticancer agent extracted from red clover plants, GAPDH, glyceraldehyde-3-phosphate dehydrogenase; *, P < 0.05 compared with the blank control group.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry has inhibitory effect on the proliferation of osteosarcoma cells and induces cell apoptosis [29] . Increasing evidence has found that artesunate was likely to induce apoptosis of HL60 promyelocyte leukemia cells and A549 lung adenocarcinoma cells by activating caspase-3 (which is mitochondria-dependent) and inhibiting Survivin gene expression. Efferth et al. also confirmed that artesunate induced apoptosis of T cells in leukemia mainly through the mitochondria-dependent pathway [30] . Thus, it could be suggested that artesunate might promote MG-63 cell apoptosis in a mitochondria-dependent manner, which was consistent with our results. It was also indicated in this study that in MG-63 cells treated with artesunate, higher concentrations of the drug resulted in lower β-catenin expression levels. β-catenin is a central component of the Wnt/β-catenin pathway [31] . When the Wnt signal pathway is activated, β-catenin will accumulate in cytoplasm, translocate to the cell nucleus and then form complexes with TCF/LEFs, thus activating the expression of various genes that play an important role in the proliferation, differentiation, apoptosis and tumorigenesis of cells [32] . When the Wnt/β-catenin pathway is inactivated, less β-catenin will translocate to the cell nucleus, which may interrupt the abovementioned pathway and disrupt normal cell cycle progression [33] . In addition, the relationship between β-catenin and cyclins is also of great significance. Inactivated cyclin D1, a transcriptional target of β-catenin, was found to contribute to deficiencies in calvarial ossification [34] . Al-Hendly et al. also reported that the expression of β-catenin and cell cycle-related proteins was associated with proliferation in HuLM cells [35] . Accumulating studies have emphasized the role of the Wnt/β-catenin pathway by investigating the expression of cyclins, CDKs and β-catenin proteins [36] [37] [38] [39] [40] . It was reported that when WIF-1 was added to renal carcinoma cells (RCCs), β-catenin expression was weakened, which reduced transduction of the Wnt signal pathway and consequently inhibit the proliferation of RCCs [41] . Moreover, Xu et al. found that the mechanism by which artesunate acts as a useful therapeutic agent for the treatment of myelodysplastic syndromes was its capacity to inhibit the Wnt/β-catenin signal pathway [42] . Our research results showed that artesunate could inhibit the proliferation of MG-63 cells by blocking β-catenin expression.
Conclusion
Artesunate can inhibit the proliferation and promote the apoptosis of MG-63 cells as well as reduce the expression levels of β-catenin. Furthermore, compared with traditional antitumor drugs, artesunate, which was extracted from natural products, exhibited advantages such as high security and low drug resistance, lending itself as a promising valid drug for treating tumors. Nevertheless, this study was limited to in vitro experiments; therefore, the regulatory mechanism of artesunate on molecules in the Wnt/β-catenin pathway still requires further investigation.
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